VivaLink Proudly Announces the Launch of a Multi Vital Monitoring Solution for Infectious Respiratory Diseases

VivaLink, a leading provider of connected healthcare solutions known for its unique medical wearable sensor platform, announces today the availability of its new multi vital ambulatory monitoring solution for Infectious Respiratory Diseases. Currently deployed in Asia, Eastern Europe and the Middle East, it is now available in the Americas and Western Europe.

“VivaLink’s continuous temperature monitor wearable, which was used for the first time in the fight against COVID-19 in our hospital, really reduced cross infection risks for our doctors and nurses due to its capabilities to provide data and vitals remotely. We used more than 200 temperature monitors throughout our hospital, and it made a huge impact in the care we were able to provide,” said Ms Zhang, deputy director of the nursing department of the Shanghai Public Health Clinical Center.

Built upon VivaLink’s proprietary ambulatory medical wearable sensor platform, the solution can easily be set up and scaled in hospitals, nursing homes and remote environments. Even pop-up hospitals with little to no network and IT infrastructure can be supported with the flexible platform. Once deployed, nurses and caregivers can effectively manage the vitals of all patients from a centralized console to easily identify changes, and view trends and history.

The multi vital monitoring solution includes:

  • Vitals: temperature, heart rate, respiratory rate, Sp02 Oxygen Saturation , and ECG
  • Reusable sensors with continuous monitoring and live streaming
  • Centralized patient monitoring application console
  • On-premise data server software
  • RPM option with patient companion app and cloud hosting
  • Up to 21 days of continuous monitoring on a single charge

“Continuous monitoring of patients’ vitals is essential for early detection of symptoms of infectious diseases, especially as we navigate the changing landscape of COVID-19,” said Jiang Li, Founder and CEO of VivaLNK. “With temperature, heart rate and Sp02, it rounds out the key vitals for infectious respiratory diseases monitoring.”

The VivaLNK solution works by automatically and continuously collecting patient vitals, and wirelessly sending it to a secure on-premise server via a Bluetooth Low Energy (BLE) WiFi router. The data is then consolidated and presented to a centralized console for caregivers. In RPM or remote field hospital deployments, an optional patient app and mobile device, and a cloud hosted application are available.

This solution is currently deployed in 15 hospitals (1,500 beds) in China for on premise in-patient monitoring of COVID-19, and in Romania, Qatar, and UAE using the mobile option.

 

SourceVivaLink

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”